2-甲基-2-[2-[2-[(2-甲基丙烷-2-基)氧基]乙氧基]乙氧基]丙烷 | 107-79-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-甲基-2-[2-[2-[(2-甲基丙烷-2-基)氧基]乙氧基]乙氧基]丙烷
• 中文别名: 2,2'-[氧代双(乙烷-2,1-二氧基)]双[2-甲基丙烷]
• 英文名称: 2-[2-(2-tert-butoxyethoxy)ethoxy]-2-methylpropane
• 英文别名: diethylene glycol di-tert-butyl ether；diethylene glycol di-t-butyl ether；di-tert-butyl diethylene glycol；di-tert-butyldiethyleneglycol；2,2'-[oxybis(ethane-2,1-diyloxy)]bis[2-methylpropane]；diethylene-glycol di-tert-butyl ether；2-Methyl-2-[2-[2-[(2-methylpropan-2-yl)oxy]ethoxy]ethoxy]propane
• CAS: 107-79-9
• 化学式: C₁₂H₂₆O₃
• 分子量: 218.337
• InChiKey: RJMRCNBBTPROCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2909199090

反应信息

• 作为反应物：
  描述：

  2-甲基-2-[2-[2-[(2-甲基丙烷-2-基)氧基]乙氧基]乙氧基]丙烷 在 Amberlyst 15 作用下， 50.0 ℃ 、1.38 MPa 条件下， 反应 6.0h， 生成 2-(2-叔-丁氧基乙氧基)乙醇
  参考文献：
  名称：

  Method of Producing Diethylene-Glycol Tert-Butyl Ether Using Isobutylene and Diethylene Glycol

  摘要：

  通常在操作反应堆之前，需要对燃料置换事故进行分析。在本发明中，通过线性组合单一置换布局的计算结果和默认放置布局的计算结果来分析燃料置换事故。通过这种方式，可以减少需要分析的置换组合数量。因此，可以节省分析时间，并确认反应堆芯的安全性。

  公开号：

  US20110160492A1
• 作为产物：
  描述：

  二乙二醇双对甲苯磺酸酯 、 lithium tert-butoxide 以 四氢呋喃 、 叔丁醇 为溶剂， 反应 24.0h， 以57%的产率得到2-甲基-2-[2-[2-[(2-甲基丙烷-2-基)氧基]乙氧基]乙氧基]丙烷
  参考文献：
  名称：

  二茂铁基恶唑啉金（i）和金（ii）配合物的非对映选择性合成，结构和反应性研究†

  摘要：

  在过去的几十年中，金络合物在软路易斯酸催化方面已显示出巨大潜力。尽管对Au络合物和平面手性金属环已进行了深入研究，但对映体纯的二茂铁基金络合物一直令人惊讶，直到本文进行了研究。在此，我们报道了平面手性二茂铁基Au（I）配合物的不对称合成。这些双核物质形成通过手性相互作用稳定的螺旋手性十元（NCCCAu）2环。在超分子固态结构中，观察到具有规则的Au⋯Au间隔的线性，锯齿形或螺旋形Au（I）线。溶解的双核实体可以被Au（I）氧化成独特的二茂铁基Au（II））具有短Au（II）–Au（II）键的络合物，而二茂铁核保持完整。然而，我们的初步研究揭示了在存在金源（Me 2 S）AuCl的情况下，二茂铁基Au（II）配合物在平面手性方面存在结构不稳定性的问题。这是通过系统研究成功解决的，该研究采用了永久的σ供体邻位保护基团（例如甲基和三甲基甲硅烷基），这阻止了差向异构事件。双核Au（I）配合物的氧化也可通过与卤化溶剂（优选为CHCl

  DOI：

  10.1039/c8dt00109j
• 作为试剂：
  描述：

  二甲基二硫 、 (4S)-4-propan-2-yl-2-(25,26,27,28-tetrapropoxy-5-pentacyclo[19.3.1.13,7.19,13.115,19]octacosa-1(24),3,5,7(28),9,11,13(27),15(26),16,18,21(25),22-dodecaenyl)-4,5-dihydro-1,3-oxazole 在 2-甲基-2-[2-[2-[(2-甲基丙烷-2-基)氧基]乙氧基]乙氧基]丙烷 、 仲丁基锂 作用下， 以 正戊烷 、 甲苯 为溶剂， 反应 7.0h， 以96%的产率得到(cS)-5-((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)-4-methylthio-25,26,27,28-tetrapropoxycalix[4]arene
  参考文献：
  名称：

  Manipulating the Diastereoselectivity of Ortholithiation in Planar Chiral Ferrocenes

  摘要：

  The sense of asymmetric ortholithiation directed by a chiral oxazoline may be inverted simply by the choice of achiral ligand. Comparison of results with a number of ferrocenyl oxazoline derivatives suggests that lithiation takes place by coordination to the oxazoline nitrogen irrespective of the ligand used.

  DOI：

  10.1021/ol4013734

文献信息

• TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas, Inc.

  公开号：US20180125821A1

  公开（公告）日：2018-05-10

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。
• CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME
  申请人：Arvinas, Inc.

  公开号：US20180215731A1

  公开（公告）日：2018-08-02

  The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

  该描述涉及cereblon E3连接酶结合化合物，包括包含相同成分的双功能化合物，这些化合物作为靶向泛素化的调节剂具有实用价值，尤其是抑制剂，可降解和/或以其他方式抑制根据本公开的双功能化合物。特别是，该描述提供了化合物，其一端含有与cereblon E3泛素连接酶结合的配体，另一端含有与目标蛋白结合的部分，使目标蛋白位于泛素连接酶附近以降解（和抑制）该蛋白。可以合成表现出广泛药理活性的化合物，与几乎所有类型的靶向多肽的降解/抑制一致。
• PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE
  申请人：SANOFI-AVENTIS DEUTSCHLAND GMBH

  公开号：US20150258207A1

  公开（公告）日：2015-09-17

  The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an insulin linker conjugate D-L, wherein D represents the insulin moiety; and -L is a non-biologically active linker moiety -L 1 represented by formula (I), wherein the dashed line indicates the attachment to one of the amino groups of the insulin by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by insulin.

  本发明涉及一种前药或其药用可接受的盐，包括胰岛素连接物D-L，其中D代表胰岛素部分；-L是一种非生物活性的连接物-L1，其由式(I)表示，虚线表示通过形成酰胺键与胰岛素的氨基团之一结合。该发明还涉及包括所述前药的药物组合物，以及它们作为治疗或预防可以通过胰岛素治疗的疾病或紊乱的药物的用途。
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES
  申请人：Arvinas, Inc.

  公开号：US20180179183A1

  公开（公告）日：2018-06-28

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为快速加速纤维肉瘤（RAF，如c-RAF、A-RAF和/或B-RAF；目标蛋白）的调节剂而发挥作用。具体而言，本公开涉及含有一端为Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源物2配体的双功能化合物，该配体与相应的E3泛素连接酶结合，并且另一端含有结合目标蛋白RAF的基团，使得目标蛋白与泛素连接酶靠近，以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白的聚集或积累，或目标蛋白的构成性激活导致的疾病或紊乱。
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE
  申请人：Arvinas, Inc.

  公开号：US20180177750A1

  公开（公告）日：2018-06-28

  The present disclosure relates to bifunctional compounds, which find utility as modulators of enhancer of zeste homolog 2 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为增强子锁定同源2的调节剂而发挥作用。具体而言，本公开涉及包含一端为Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源2配体的双功能化合物，该配体与相应的E3泛素连接酶结合，另一端含有结合目标蛋白的基团，使目标蛋白靠近泛素连接酶以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白聚集或积累导致的疾病或紊乱。